Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA trimmed its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 34.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,686 shares of the company's stock after selling 22,490 shares during the period. Primecap Management Co. CA's holdings in Guardant Health were worth $1,335,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of GH. Arizona State Retirement System grew its holdings in Guardant Health by 1.1% during the 4th quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock valued at $1,089,000 after purchasing an additional 403 shares during the last quarter. Jones Financial Companies Lllp boosted its position in shares of Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after buying an additional 817 shares during the period. Fiduciary Alliance LLC grew its stake in shares of Guardant Health by 7.6% during the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock valued at $363,000 after buying an additional 836 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Guardant Health in the fourth quarter worth approximately $26,000. Finally, Van ECK Associates Corp lifted its stake in shares of Guardant Health by 47.4% during the 4th quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock worth $88,000 after acquiring an additional 929 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Remove Ads

Guardant Health Trading Up 1.4 %

Shares of GH traded up $0.64 during trading hours on Monday, hitting $46.74. The company had a trading volume of 1,505,161 shares, compared to its average volume of 2,145,772. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $50.89. The company's fifty day moving average price is $43.85 and its two-hundred day moving average price is $33.63. The company has a market capitalization of $5.77 billion, a PE ratio of -13.13 and a beta of 1.50.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GH shares. Canaccord Genuity Group upped their price objective on Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, February 24th. Scotiabank upped their price target on shares of Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Stifel Nicolaus raised their price target on shares of Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Guggenheim reissued a "buy" rating and issued a $56.00 price objective on shares of Guardant Health in a research report on Monday, February 24th. Finally, The Goldman Sachs Group upped their target price on shares of Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Twenty analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $48.40.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.